Abstract: Our findings suggest that constitutional methylation of LTBP4 CpG island 102 may be associated with increased CRC risk. Identification of additional cases is needed to confirm the existence of a novel CRC predisposition syndrome driven by epigenetic inactivation of LTBP4, potentially also linked to other clinical phenotypes associated with LTBP4 deficiency, such as pulmonary emphysema. Whether constitutional BRCA1 methylation contributes to CRC risk remains to be determined.
Introduction
Hereditary colorectal cancer (CRC) is traditionally attributed to pathogenic DNA variants in mismatch repair (MMR) genes (Lynch Syndrome) or polyposis-associated genes. However, a significant portion of early-onset or familial CRC cases remain "genetically unsolved," showing no clear mutations despite strong clinical indicators of heritability. This study, published in Clinical Epigenetics, investigates the role of constitutional epimutations—primary monoallelic promoter methylation present from birth—as a potential "dark matter" driver of cancer predisposition.
Study Design and Methodology
The researchers employed a comprehensive multi-omic pipeline to screen for and validate epigenetic alterations in patients lacking traditional genetic mutations. The discovery phase involved genome-wide methylation profiling of blood DNA from 46 MMR-proficient, early-onset/familial CRC patients using the Illumina Infinium MethylationEPIC BeadChip.
To distinguish primary epimutations from secondary ones (caused by nearby DNA sequence changes), the team utilized Whole-Genome Sequencing (WGS) and Whole-Exome Sequencing (WES). Functional validation was performed by correlating methylation levels with RNA expression using data from the Colonomics project, and AI-driven pathology was used to assess Homologous Recombination Deficiency (HRD) in specific cases.
Identification of LTBP4 Epimutations
The study's most significant finding was the identification of a patient (P-38) with constitutional methylation of CpG island 102 in the LTBP4 gene. LTBP4 is a critical regulator of the TGF-β signaling pathway, which is frequently disrupted in CRC development.
As shown in the methylation profiling data, patient P-38 exhibited an average β-value of approximately 0.34, which is consistent with monoallelic methylation (where one allele is silenced while the other remains active). WGS confirmed the absence of underlying genetic variants, classifying this as a primary epimutation. Interestingly, the patient also presented with pulmonary emphysema, a condition linked to LTBP4 deficiency in animal models and human syndromes, providing further clinical evidence of the epimutation's functional impact.
Somatic Parallelism and BRCA1 Mosaicism
While constitutional LTBP4 methylation is rare (found in 2.2% of the discovery cohort), the authors discovered that somatic (tumor-specific) methylation of the same region is common in sporadic CRC. This somatic silencing strongly correlates with gene downregulation, suggesting that LTBP4 is a frequent target for epigenetic inactivation during tumorigenesis.
Additionally, the study identified low-level mosaic methylation of the BRCA1 promoter in another patient. While BRCA1 is primarily associated with breast and ovarian cancers, its potential role in CRC risk remains an area of active investigation, though a definitive "second hit" in the tumor was not identified in this specific case.
Conclusion and Future Directions
This research highlights LTBP4 as a novel candidate for an epigenetically-regulated cancer predisposition gene. The study suggests that constitutional epimutations may explain a portion of the "missing heritability" in early-onset CRC. However, the small sample size (n=1 for the primary LTBP4 finding) necessitates screening larger cohorts to definitively establish a new predisposition syndrome. Future functional studies will be essential to determine which LTBP4 isoforms are most critical for maintaining colonic health and preventing malignant transformation.
Summary updated